APOHEALTH Famciclovir (500mg) Famciclovir Once 3 Tablets
Ask your pharmacist about this product. Always read the label and follow the directions for use.
Code: 10052658
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
$14.45
Choose delivery option
Trending Products
Product Overview
Apohealth Famciclovir cold sores is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults aged 18 years and over. It can also be used for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of rash.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at care@healthylife.com.au. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
APOHEALTH Famciclovir (500mg) Famciclovir Once 3 Tablets
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
$14.45
Choose delivery option
Product Overview
Apohealth Famciclovir cold sores is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults aged 18 years and over. It can also be used for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of rash.